Methodological and conceptual considerations for examining the α-FAtE scoring in unresectable hepatocellular carcinoma
Author:
Open Access
- 6 January 2025
- journal article
- letter
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (1) , e010840
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinomaInternational Journal of Cancer, 2023
- Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patientsBMC Cancer, 2021
- PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinomaBMC Cancer, 2021
- Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinomaOncotarget, 2019
- Eosinophilic Count as a Biomarker for Prognosis of Melanoma Patients and Its Importance in The Response to ImmunotherapyImmunotherapy, 2017
- Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with IpilimumabClinical Cancer Research, 2016
- Eosinophils and CancerCancer Immunology Research, 2014
- Diagnostic and Prognostic Role of alpha-Fetoprotein in Hepatocellular Carcinoma: Both or Neither?American Journal of Gastroenterology, 2006
- Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for α‐fetoprotein alone and those seropositive for des‐γ‐carboxy prothrombin alone1Journal of Gastroenterology and Hepatology, 2001
- Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV statusJournal of Hepatology, 2001